1MT9 - Header Asymmetric Unit

HEADER HYDROLASE 20-SEP-02 1MT9

TITLE VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: TITLE 2 STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY

COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV-1 PROTEASE; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: P1-P6 GAG SUBSTRATE DECAPEPTIDE; COMPND 10 CHAIN: P; COMPND 11 ENGINEERED: YES

SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: TAP106; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: PXC35-PEN18; SOURCE 9 MOL_ID: 2; SOURCE 10 SYNTHETIC: YES; SOURCE 11 OTHER_DETAILS: THIS PEPTIDE SEQUENCE OCCURS NATURALLY IN SOURCE 12 GAG OF HIV-1

KEYWDS MATRIX, CAPSID, GAG CLEAVAGE, DRUG RESISTANCE, SUBSTRATE KEYWDS 2 RECOGNITION, HYDROLASE

EXPDTA X-RAY DIFFRACTION

AUTHOR M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING,C.A.SCHIFFER

REVDAT 2 24-FEB-09 1MT9 1 VERSN REVDAT 1 07-JAN-03 1MT9 0

JRNL AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING, JRNL AUTH 2 C.A.SCHIFFER JRNL TITL VIABILITY OF DRUG-RESISTANT HUMAN IMMUNODEFICIENCY JRNL TITL 2 VIRUS TYPE 1 PROTEASE VARIANT: STRUCTURAL INSIGHTS JRNL TITL 3 FOR BETTER ANTIVIRAL THERAPY JRNL REF J.VIROL. V. 77 1305 2003 JRNL REFN ISSN 0022-538X JRNL PMID 12502847 JRNL DOI 10.1128/JVI.77.2.1306-1315.2003

REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC REMARK 1 TITL 2 SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE REMARK 1 REF J.MOL.BIOL. V. 301 1207 2000 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.2000.4018 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL SUBSTRATE SHAPE DETERMINES SPECIFICITY OF REMARK 1 TITL 2 RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF REMARK 1 TITL 3 CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES REMARK 1 REF STRUCTURE V. 10 369 2002 REMARK 1 REFN ISSN 0969-2126 REMARK 1 DOI 10.1016/S0969-2126(02)00720-7 REMARK 1 REFERENCE 3 REMARK 1 AUTH N.M.KING,L.MELNICK,M.PRABU-JEYABALAN,E.A.NALIVAIKA, REMARK 1 AUTH 2 S.-S.YANG,Y.GAO,X.NIE,C.ZEPP,D.L.HEEFNER, REMARK 1 AUTH 3 C.A.SCHIFFER REMARK 1 TITL LACK OF SYNERGY FOR INHIBITORS TARGETING A REMARK 1 TITL 2 MULTI-DRUG RESISTANT HIV-1 PROTEASE REMARK 1 REF PROTEIN SCI. V. 11 418 2002 REMARK 1 REFN ISSN 0961-8368 REMARK 1 DOI 10.1110/PS.2520102

REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS.

REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 0.9 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 32.84 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 172172.140 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 95.4 REMARK 3 NUMBER OF REFLECTIONS : 12659 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.179 REMARK 3 FREE R VALUE : 0.210 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.300 REMARK 3 FREE R VALUE TEST SET COUNT : 1272 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.07 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 92.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1002 REMARK 3 BIN R VALUE (WORKING SET) : 0.2200 REMARK 3 BIN FREE R VALUE : 0.2900 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 9.30 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 103 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.028 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1570 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 88 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 12.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 23.80 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.66000 REMARK 3 B22 (A**2) : -0.64000 REMARK 3 B33 (A**2) : 1.30000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.26 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.18 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.80 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.00 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.87 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.37 REMARK 3 BSOL : 67.39 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL

REMARK 4 REMARK 4 1MT9 COMPLIES WITH FORMAT V. 3.15, 01-DEC-08

REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 27-SEP-02. REMARK 100 THE RCSB ID CODE IS RCSB017167.

REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-NOV-99 REMARK 200 TEMPERATURE (KELVIN) : 298 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : YALE MIRRORS REMARK 200 OPTICS : YALE MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : R-AXIS REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 12659 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 32.840 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.4 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.09000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 7.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 92.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.33000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1MTR REMARK 200 REMARK 200 REMARK: NULL

REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.41 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.06 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SODIUM PHOSPHATE, SODIUM CITRATE, REMARK 280 AMMONIUM SULPHATE, PH 6.2, VAPOR DIFFUSION, HANGING DROP AT REMARK 280 298K

REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.63250 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 30.96300 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.56650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 30.96300 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.63250 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.56650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL

REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ENTIRE DIMER IS PROVIDED IN THE COORDINATE SET AND REMARK 300 THE MONOMERS ARE DISTINGUISHED BY THE CHAIN IDS `A' AND `B'. THE REMARK 300 DECAMER SEQUENCE CORRESPONDING TO THE MA-CA CLEAVAGE SITE OF HIV REMARK 300 -1 GAG POLYPROTEIN.

REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 6550 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9030 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -60.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, P REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000

REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS(M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A 7 CG CD CE NZ REMARK 470 ARG A 14 CG CD NE CZ NH1 NH2 REMARK 470 ASN A 37 CG OD1 ND2 REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 LYS A 55 CG CD CE NZ REMARK 470 LYS B 7 CG CD CE NZ REMARK 470 GLN B 18 CG CD OE1 NE2 REMARK 470 LYS B 41 CG CD CE NZ REMARK 470 LYS B 43 CG CD CE NZ REMARK 470 LYS B 45 CG CD CE NZ REMARK 470 LYS B 55 CG CD CE NZ REMARK 470 LYS B 70 CG CD CE NZ REMARK 470 ARG P 1 CG CD NE CZ NH1 NH2

REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 35 127.95 -39.16 REMARK 500 GLU B 35 132.16 -39.61 REMARK 500 PHE P 5 44.61 -90.93 REMARK 500 REMARK 500 REMARK: NULL

REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A 517 DISTANCE = 5.89 ANGSTROMS REMARK 525 HOH A 521 DISTANCE = 5.46 ANGSTROMS REMARK 525 HOH A 532 DISTANCE = 6.86 ANGSTROMS REMARK 525 HOH A 538 DISTANCE = 5.30 ANGSTROMS REMARK 525 HOH A 540 DISTANCE = 6.68 ANGSTROMS REMARK 525 HOH A 545 DISTANCE = 6.53 ANGSTROMS REMARK 525 HOH A 548 DISTANCE = 8.34 ANGSTROMS

REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 B 501 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 B 502 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 B 503 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A 504 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A 506 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A 507

REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1KJ4 RELATED DB: PDB REMARK 900 INACTIVE WILD-TYPE HIV-1 PROTEASE (D25N) COMPLEXED WITH ITS REMARK 900 GAG SUBSTRATE PEPTIDE MA-CA. REMARK 900 RELATED ID: 1MTR RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL REMARK 900 PEPTIDOMIMETIC INHIBITOR REMARK 900 RELATED ID: 1MT7 RELATED DB: PDB REMARK 900 RELATED ID: 1MT8 RELATED DB: PDB REMARK 900 RELATED ID: 1MTB RELATED DB: PDB

DBREF 1MT9 A 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1MT9 B 1 99 UNP P03369 POL_HV1A2 57 155

SEQADV 1MT9 LYS A 7 UNP P03369 GLN 63 ENGINEERED SEQADV 1MT9 ASN A 25 UNP P03369 ASP 81 ENGINEERED SEQADV 1MT9 ALA A 82 UNP P03369 VAL 138 ENGINEERED SEQADV 1MT9 LYS B 7 UNP P03369 GLN 63 ENGINEERED SEQADV 1MT9 ASN B 25 UNP P03369 ASP 81 ENGINEERED SEQADV 1MT9 ALA B 82 UNP P03369 VAL 138 ENGINEERED

SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 P 10 ARG PRO GLY ASN PHE LEU GLN SER ARG PRO

HET PO4 B 501 5 HET PO4 B 502 5 HET PO4 B 503 5 HET PO4 A 504 5 HET PO4 A 506 5 HET PO4 A 507 5

HETNAM PO4 PHOSPHATE ION

FORMUL 4 PO4 6(O4 P 3-) FORMUL 10 HOH *88(H2 O)

HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 86 THR B 91 1 6

SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 O THR A 96 N ASN B 98 SHEET 4 A 4 GLN B 2 ILE B 3 -1 N ILE B 3 O LEU A 97 SHEET 1 B 3 LEU A 10 VAL A 11 0 SHEET 2 B 3 ALA A 22 LEU A 24 -1 N ALA A 22 O VAL A 11 SHEET 3 B 3 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 1 C 5 THR A 31 LEU A 33 0 SHEET 2 C 5 HIS A 69 VAL A 77 1 O THR A 74 N THR A 31 SHEET 3 C 5 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 4 C 5 ILE A 13 ILE A 15 -1 N ARG A 14 O GLU A 65 SHEET 5 C 5 GLN A 18 LEU A 19 -1 O GLN A 18 N ILE A 15 SHEET 1 D 4 THR A 31 LEU A 33 0 SHEET 2 D 4 HIS A 69 VAL A 77 1 O THR A 74 N THR A 31 SHEET 3 D 4 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 4 D 4 LYS A 43 GLY A 49 -1 O LYS A 43 N GLN A 58 SHEET 1 E 3 LEU B 10 VAL B 11 0 SHEET 2 E 3 ALA B 22 LEU B 24 -1 N ALA B 22 O VAL B 11 SHEET 3 E 3 ILE B 84 ILE B 85 1 N ILE B 85 O LEU B 23 SHEET 1 F 5 THR B 31 LEU B 33 0 SHEET 2 F 5 HIS B 69 VAL B 77 1 O THR B 74 N THR B 31 SHEET 3 F 5 GLY B 52 ILE B 66 -1 N ARG B 57 O VAL B 77 SHEET 4 F 5 ILE B 13 ILE B 15 -1 N ARG B 14 O GLU B 65 SHEET 5 F 5 GLN B 18 LEU B 19 -1 O GLN B 18 N ILE B 15 SHEET 1 G 4 THR B 31 LEU B 33 0 SHEET 2 G 4 HIS B 69 VAL B 77 1 O THR B 74 N THR B 31 SHEET 3 G 4 GLY B 52 ILE B 66 -1 N ARG B 57 O VAL B 77 SHEET 4 G 4 LYS B 43 GLY B 49 -1 O LYS B 43 N GLN B 58

SITE 1 AC1 4 PRO A 1 HIS B 69 LYS B 70 PHE B 99 SITE 1 AC2 3 PRO B 1 ARG B 57 HIS B 69 SITE 1 AC3 5 GLY A 16 GLY A 17 ARG B 14 GLY B 17 SITE 2 AC3 5 HOH B 533 SITE 1 AC4 3 LYS A 7 ARG A 8 ARG B 87 SITE 1 AC5 3 GLY A 73 THR A 74 ASN A 88 SITE 1 AC6 5 PRO A 39 GLY A 40 HOH A 547 MET B 36 SITE 2 AC6 5 ASN B 37

CRYST1 51.265 59.133 61.926 90.00 90.00 90.00 P 21 21 21 8

ORIGX1 1.000000 0.000000 0.000000 0.00000

ORIGX2 0.000000 1.000000 0.000000 0.00000

ORIGX3 0.000000 0.000000 1.000000 0.00000

SCALE1 0.019506 0.000000 0.000000 0.00000

SCALE2 0.000000 0.016911 0.000000 0.00000

SCALE3 0.000000 0.000000 0.016148 0.00000